HC Wainwright & Co. Reiterates Buy on AC Immune, Maintains $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on AC Immune (NASDAQ:ACIU) and maintained a price target of $16, indicating confidence in the company's future performance.
September 18, 2024 | 10:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on AC Immune, maintaining a $16 price target. This suggests confidence in the company's future performance and potential stock price appreciation.
The reiteration of a Buy rating and maintenance of a $16 price target by HC Wainwright & Co. indicates a positive outlook for AC Immune. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100